Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Reproductive health researchers found a rarely discussed "pathway" between the effect and its unexpected cause.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...

Lyn Iemma, aged 75 years at the time of writing, would not describe her life as dramatic. Born and raised in Perth, WA, Australia, this thriving but relaxed city is the place she has always called ...

My name is Tawanda, and I will be your operator ... reflecting the strength and durability of our key franchises, primarily, Dupixent, Libtayo, and EYLEA and EYLEA HD. 2024 was also a year in ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi SNY for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat ...

Despite Eylea's market challenges, Dupixent's strong performance and future ... which translates to an annual yield of ~0.53% - a long way behind the "Big Pharma" average yield of ~3%, but an ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent ... Ironically, the best way to mitigate these risks ...

Amid the blockbuster gains, some stocks have gone the opposite way, tanking to levels not seen ... The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales ...

Microsoft has (very quietly) announced that it will be changing the way account sign-ins work in February – and the new system could pose a significant security risk for some users. Squirreled ...

The sum-of-the-parts way and the platform way. Regeneron has 11 approved drugs but two comprise most of the cash flows. The two are Eylea and Dupixent.